SCHEMBL2265319

SCHEMBL2265319

Cn1c(=O)[nH]c2cnc(Cl)nc21

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.60
MEN1 O00255 1/20 0.60
PABPC1 P11940 1/20 0.60
KMT2A Q03164 1/20 0.60
TYRO3 Q06418 1/20 0.46
DYRK1B Q9Y463 1/20 0.46
IDH1 O75874 1/20 0.46
KDM4E B2RXH2 3/20 0.45
GAA P10253 2/20 0.45
PDE3B Q13370 4/20 0.42
PDE3A Q14432 4/20 0.42
CYP3A4 P08684 1/20 0.40
MAPK1 P28482 1/20 0.40
PMP22 Q01453 1/20 0.40
RXFP1 Q9HBX9 1/20 0.38
HPGD P15428 2/20 0.38
HTT P42858 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ADORA3 P0DMS8 2/20 0.36
P2RY12 Q9H244 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29864436 1.00 LMNA (0.60) LMNAMEN1PABPC1KMT2ATYRO3
SCHEMBL23948547 0.83 DAO (0.47) LMNAMEN1PABPC1KMT2ATYRO3
SCHEMBL23620554 0.82 MEN1 (0.44) LMNAMEN1PABPC1KMT2ATYRO3
SCHEMBL17813486 0.81 LMNA (0.53) LMNAMEN1PABPC1KMT2AIDH1
SCHEMBL10292522 0.79 GAA (0.53) LMNAMEN1PABPC1KMT2AIDH1
SCHEMBL1782345 0.79 USP1 (0.43) LMNAMEN1PABPC1KMT2ATYRO3
SCHEMBL22419384 0.77 LMNA (0.49) LMNAMEN1PABPC1KMT2AIDH1
SCHEMBL26024589 0.77 LMNA (0.49) LMNAMEN1PABPC1KMT2AIDH1
SCHEMBL2266857 0.77 CYP1A2 (0.53) LMNAMEN1PABPC1KMT2AIDH1
SCHEMBL4191402 0.76 PDE4A (0.45) LMNAMEN1PABPC1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260008780-A1 SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES NODTHERA LTD (GB) 2026-01-08 US disclosed
EP-4536350-A1 SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES Nodthera Limited (GB) 2025-04-16 EP disclosed
US-20240239790-A1 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor LIFEARC (GB) 2024-07-18 US disclosed
EP-4305032-A1 7-MORPHOLINO-1,6-NAPHTHYRIDIN-5-YL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF USEFUL AS DNA-PK INHIBITOR Admare Therapeutics Society (CA) 2024-01-17 EP disclosed
WO-2023240134-A1 SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES NodThera Limited (GB) 2023-12-14 WO disclosed
WO-2023240134-A1 SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES NodThera Limited (GB) 2023-12-14 WO disclosed
WO-2022187965-A1 7-MORPHOLINO-1,6-NAPHTHYRIDIN-5-YL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF USEFUL AS DNA-PK INHIBITOR adMare Therapeutics Society (CA) 2022-09-15 WO disclosed
US-20200115343-A1 FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. 2020-04-16 US disclosed
US-20200115343-A1 FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. 2020-04-16 US disclosed
US-10577329-B2 Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors FORMA THERAPEUTICS, INC. (US) 2020-03-03 US disclosed
US-8735406-B2 8-oxodihydropurine derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2014-05-27 US disclosed
US-8735406-B2 8-oxodihydropurine derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2014-05-27 US disclosed
EP-2476682-A1 8-OXODIHYDROPURINE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2012-07-18 EP disclosed
US-20120172347-A1 8-OXODIHYDROPURINE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-07-05 US disclosed
US-20120172347-A1 8-OXODIHYDROPURINE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-07-05 US disclosed
US-20110201629-A1 CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2011-08-18 US disclosed
US-20110201629-A1 CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2011-08-18 US disclosed
WO-2011092293-A2 CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2011-08-04 WO disclosed
WO-2011092293-A2 CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2011-08-04 WO disclosed
WO-2011030798-A1 8-OXODIHYDROPURINE DERIVATIVE 大日本住友製薬株式会社 (JP) 2011-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239790-A1 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor DCK, ERCC2, POLK LMNA 604/4885MEN1 4311/4885PABPC1 151/4885
US-20120172347-A1 8-OXODIHYDROPURINE DERIVATIVE FAAH, FAAH2, TPMT LMNA 3252/4885MEN1 4651/4885PABPC1 1025/4885
US-10577329-B2 Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors IDH1, IDH3A, IDH3B LMNA 2949/4885MEN1 2243/4885PABPC1 4035/4885
US-20260008780-A1 SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES NOD1, NLRP3, CASP1 LMNA 650/4885MEN1 1374/4885PABPC1 1482/4885
US-20110201629-A1 CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS CRHR1, CRHR2, CRH LMNA 4449/4885MEN1 2265/4885PABPC1 3171/4885
US-20200115343-A1 FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS IDH1, IDH3A, IDH3B LMNA 2949/4885MEN1 2243/4885PABPC1 4035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.